Company: CERO
Filing Date: 2025-04-28
Form Type: 10-K/A
Source: 0001213900-25-036075
Chunk: 19

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-28
Form: 10-K/A
Chunk 19
---
 relating to compensation and benefits of employees. |

Nominating and Corporate Governance Committee The members of our nominating and corporate governance committee are Dr. Rolfe, Ms. LaPorte and Mr. Byrnes. Dr. Rolfe serves as the chairperson of the committee. Our board of directors has determined that each of Dr. Rolfe, Ms. LaPorte and Mr. Byrnes is independent under the applicable Nasdaq listing standards. 8 The nominating and corporate governance committee’s main function is to consider candidates for board membership and oversee our corporate governance policies, reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. The nominating and corporate governance committee’s responsibilities include, among other things:

| ● | recommending to the board of directors for its approval criteria for board of directors and committee 
 membership;                                                                                           |

| ● | establishing a process for identifying and evaluating board of director candidates, including nominees 
 recommended by stockholders;                                                                           |

| ● | identifying individuals qualified to become members of the board of directors; |

| ● | recommending to the board of directors the persons to be nominated for election as directors and to each 
 of the committees of the board of directors;                                                             |

| ● | developing and recommending to the board of directors corporate governance guidelines and periodically   
 reviewing those guidelines and the code of conduct and business ethics and recommending any changes; and |

| ● | overseeing a periodic evaluation of the board of directors and its committees. |

Board and Committee Meetings Attendance During the fiscal year ended December 31, 2024, our board of directors met 16 times, our Audit Committee met four times, and our Compensation Committee met six times. Our Nominating and Corporate Governance Committee did not hold a meeting in 2024. Each board member attended 75% or more of the aggregate number of meetings of the board of directors and meetings of the committees on which he or she served during the fiscal year ended December 31, 2024, for which he or she was a director or committee member. Director Attendance at Annual Meeting of Stockholders We encourage our directors to attend our annual meetings of stockholders. We did not hold an annual meeting of stockholders during the fiscal year ended December 31, 2024. Compensation Committee Interlocks and Insider Participation During the fiscal year ended December 31, 2024, Mr. Ehrlich served as a member of our Compensation Committee from the closing of the Business Combination until his appointment as our